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Abstract
Background Rapidly disintegrating or ‘fast-melt’ oral
formulations have been developed recently to facilitate
drug intake among patients. Even though these formula-
tions have helped to improve therapy adherence, some of
their limitations include: the dissolution time, their facility
to be swallowed, and the dosage strengths that may be
accommodated. To overcome these limitations, a novel,
porous, quickly disintegrating, and easier-to-swallow fast-
melt formulation based on powder-liquid, three-dimen-
sional printing (3DP) technology has been developed.
Objective To determine and compare the relative
bioavailability of a novel 3DP fast melt containing leve-
tiracetam in healthy male and female subjects.
Methods This study included 33 subjects in a three-way
crossover design. The 3DP fast-melt formulation was
compared against the conventional immediate-release
tablet of levetiracetam (Keppra) after a single 1000-mg
dose administration under fasting conditions following the
bioequivalence criteria used by the US Food and Drug
Administration. This study also evaluated the food effect
on the bioavailability of the levetiracetam 3DP fast melt. A
small sip of liquid was used to administer the fast-melt
formulation.
Results The novel 3DP fast melt showed rapid oral dis-
integration (mean duration of 11 s from a sip of water to
completion of swallowing) following its administration,
and did not affect the pharmacokinetic profile of leve-
tiracetam. A lower absorption peak was observed after
administration of the 3DP fast melt under fed conditions, as
expected. In addition, time of maximum measured plasma
concentration was delayed by approximately 3.5 h under
fed conditions. These effects are unlikely to be of clinical
significance with long-term administration, and may help
reduce the adverse events and facilitate compliance.
Finally, no change in the oral mucosa was observed with
the 3DP fast melt while being as safe and well tolerated as
the standard levetiracetam tablet.
Conclusion This study quantified the rapid disintegration
of the 3DP levetiracetam fast melt and confirmed its
equivalent rate and extent of absorption to the conventional
immediate-release tablet in the fasted state, using standard
bioequivalence criteria.
Key Points
A novel levetiracetam three-dimensional printing
(3DP) fast-melt formulation rapidly disintegrates
within seconds in the mouth, when exposed to a
small volume of liquid.
The levetiracetam 3DP fast melt was shown to be
bioequivalent to the conventional tablet under fasting
conditions.
The 3DP technology enables the production of
highly porous, rapidly disintegrating oral
formulations, which can incorporate higher doses of
active drug, facilitating therapy adherence.
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1 Introduction
1.1 Background and Objectives
Levetiracetam is a second-generation antiepileptic drug
(AED) currently approved by the US Food and Drug
Administration (FDA) as an adjunctive treatment in
patients with partial-onset seizures [1]. Levetiracetam is
structurally unrelated to any other antiepileptic drug class
and has a novel mechanism of action [1, 2]. Levetiracetam
is well tolerated, and adverse events (AEs) are limited
primarily to the central nervous system such as asthenia,
somnolence, dizziness, and headache [1, 2].
Levetiracetam is rapidly and almost completely absor-
bed ([95 %) following oral administration and exhibits
linear pharmacokinetics (PK) over a 500- to 5000-mg dose
range. Levetiracetam is unlikely to compete with other
drugs for protein-binding sites. Finally, its metabolism is
minimal and not dependent on the hepatic cytochrome
P450 enzyme system, indicating that clinical drug inter-
actions are unlikely [1]. The efficacy and tolerability of
levetiracetam make it a desirable AED [2]. Besides the oral
tablet formulation, other formulations of levetiracetam
include oral solution, extended-release tablets, and injec-
tion for intravenous use [3].
Poor adherence to therapy is an issue in the young, the
older population, and in some other patients. Factors that
may improve adherence include convenience of dosing,
ease of use, drug tolerability, and patient satisfaction [4, 5].
Difficulty in swallowing is another barrier to medication
adherence and is noted to occur in nearly one third of
psychiatric patients, nearly a quarter of primary care
patients, and more often in women than in men [5, 6].
The oral route remains the preferred route of drug
administration owing to its convenience, good patient
compliance, and low medicine production costs [7]. While
an oral liquid (solution or suspension) supplied in bottles is
easy to swallow, it lacks the convenience and portability of
a premeasured unit dose, is not spill proof, and may not
adequately mask the taste of active and inactive ingredi-
ents. ‘Fast-melt’ preparations such as orally disintegrating
tablets (ODTs) were developed in the 1990s to address the
swallowing difficulty of conventional tablets and capsules,
without the limitations associated with oral liquids. Several
ODT products are currently marketed for drugs in various
therapeutic areas including AEDs [8, 9]. While these ODT
products have been designed to be administered without
water and disintegrate on the tongue in generally less than
30 s, the vast majority have only incorporated limited
amounts of the active drug product (e.g., 10–30 mg), which
has limited the application of ODT technology to higher-
dose drug products. A recent innovation, based on powder-
liquid three-dimensional printing (3DP) technology, has
been developed to overcome these limitations. The 3DP
technology approach enables the production of highly
porous, rapidly disintegrating oral formulations, which can
incorporate up to 1000-mg of the active drug product per
tablet. Importantly, the 3DP technology approach incor-
porates various taste-masking techniques and requires each
unit dose to be taken with a small volume of liquid for ease
of administration and swallowing.
When comparing an ODT with a conventional tablet
formulation, one of the criteria required by the regulatory
authorities is to conduct a comparative bioavailability
study, which for example may use bioequivalence criteria
to confirm similar PK behavior despite the differences in
form, mode of administration, and final formulation.
Although different types of rapidly disintegrating tablets
exist, with different rates of disintegration and/or dissolu-
tion, the bioequivalence criteria are still the same.
The primary objectives of the study were to determine
and compare the levetiracetam plasma concentrations fol-
lowing a single 1000-mg administration of the levetirac-
etam 3DP fast-melt formulation (test product) and an
immediate-release, film-coated Keppra tablet (reference
product) in normal healthy volunteers, and to evaluate the
effect of food consumption on the PK profile of leve-
tiracetam 3DP fast melt. The secondary objective of the
study was to determine the safety and tolerability of leve-
tiracetam 3DP fast melt compared with Keppra film-coated
tablets in healthy volunteers. In addition, the disintegration
time for the 3DP fast melt was measured.
2 Methods
2.1 Study Design and Treatment
This randomized, open-label, single-dose, three-period,
three-treatment, three-sequence crossover study was con-
ducted in October 2013 in Canada (Algorithme Pharma
Inc., Montreal, Quebec, Canada). Thirty-three subjects
were randomly assigned to one of three sequences: ABC,
BCA, and CAB. The randomization code list was gener-
ated using the Algorithme Pharma-developed application
named Clinical according to the study design, the number
of subjects, and the sequence of drug administration, and
using blocks with a size of three. In each study period,
subjects fasted overnight prior to and for at least 4 h after
dosing or prior to receiving a FDA-compliant, high-fat,
high-calorie meal. The treatment periods were separated by
a washout period of 7 days. Subjects were dosed with the
levetiracetam test product (Treatment-1, A) and the refer-
ence product (Treatment-2, B) under fasting conditions,
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and also received the test product 30 min after an FDA-
compliant, high-fat, high-calorie breakfast (Treatment-3,
C).
Following intra-oral placement of the levetiracetam 3DP
fast melt (test product) directly on the tongue, subjects
were instructed to wet their mouth by taking a sip from a
cup containing 30 mL of water at ambient temperature
without swallowing the dosage unit. Once the dosage unit
was disintegrated, subjects were asked to swallow the
medication. The elapsed time between water intake and
completion of swallowing was recorded for all subjects.
This elapsed time from sip to swallowing represented the
recorded disintegration time for the fast-melt test product.
Upon request by the subject, additional water (in amounts
of 30 mL) was to be provided; and actual amounts of water
intake were documented. The reference product (Keppra
tablet) was administered with 240 mL of water at ambient
temperature.
A novel, 1000-mg 3DP fast-melt formulation of leve-
tiracetam manufactured by Aprecia Pharmaceuticals
Company (Blue Ash, OH, USA), was compared with
Keppra 1000-mg film-coated tablets, manufactured by
UCB Inc., Smyrna, GA, USA. Study drugs were stored at
the study site at a controlled room temperature (15–30 C).
2.2 Participants
Subjects were healthy men or non-pregnant women, aged
between 18 and 50 years, with a body mass index C18.50
and \30.00 kg/m2. Efforts were made to enroll a similar
proportion of male and female subjects. Subjects were
screened within 28 days prior to drug administration. The
screening visit included medical history and demographic
data collection including alcohol and smoking habits. A
complete physical examination (head, eyes, ears, nose,
throat, neck, chest, back, abdomen, extremities, and neu-
rological function), the measurement of vital signs (pulse
rate, blood pressure, and body temperature), a 12-lead
electrocardiogram (ECG), neurological function (cognitive,
cranial nerves, sensory, motor, coordination, and equilib-
rium), and laboratory tests (hematology, serum chemistry,
and urinalysis) were performed.
No prescription medication, apart from hormonal con-
traceptives and hormone replacement therapy, was allowed
for 28 days prior to dosing and during the study. Over-the-
counter products had to be stopped 7 days before dosing, as
well as grapefruit/pomelo nutritional sources. Only non- or
ex-smokers were allowed, and alcohol and food or bever-
ages containing xanthines were to be avoided 58 h before
each dosing. Subjects were asked to refrain from heavy
exercise during the study. No concomitant medications
were allowed during the study.
2.3 Pharmacokinetic Endpoints
In each study period, blood samples were collected prior to
and 0.17, 0.25, 0.33, 0.50, 0.67, 0.83, 1.00, 1.33, 1.67, 2.00,
2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00,
24.00, and 36.00 h after drug administration for PK mea-
surements of levetiracetam.
Blood samples were collected in pre-cooled K2 EDTA
Vacutainers. Following blood collection, samples were
centrifuged at a temperature of 4 C nominal and at
approximately 1500g for 10 min. The plasma obtained was
transferred in polypropylene culture tubes and was main-
tained in an ice-water bath until stored in the clinical
freezers. Tubes were labeled with a code number that did
not reveal the identity of the treatments. Samples were
frozen at a temperature of -20 C nominal.
Levetiracetam plasma samples were assayed through a
validated liquid chromatography-tandem mass spectrome-
try analytical method. Sample pre-treatment involved the
protein precipitation extraction of levetiracetam from
0.1 mL of human plasma; levetiracetam-D6 was used as
the internal standard. The compound was quantified using
reversed-phase, high-performance liquid chromatography
with a triple quadrupole mass spectrometer equipped with a
turbo-assisted ionspray ionization source in positive mode
over a theoretical concentration range of 0.250–65.000 lg/
mL. The concentrations were calculated using peak area
ratios and the linearity of the calibration curve was deter-
mined using least-squares regression analysis employing a
weighted (1/x2) linear (y = mx ? b) for levetiracetam.
The following PK parameters were calculated: maxi-
mum observed plasma concentration (Cmax), time of
maximum measured plasma concentration (Tmax), cumu-
lative area under the plasma concentration time curve
calculated from 0 to time of the last quantifiable concen-
tration using the trapezoidal rule (linear trapezoidal linear
interpolation) (AUC0–T), extrapolated area under the
plasma concentration time curve to infinity (AUC0–?), and
half-life of elimination (Thalf). The terminal-phase estima-
tion was based on maximizing the coefficient of determi-
nation. Non-compartmental PK analyses were performed
using Phoenix WinNonlin, version 6.3 (Certara USA,
Inc., Princeton, NJ).
2.4 Safety and Tolerability Endpoints
Safety monitoring during the study was performed through
vital signs and 12-lead ECGs performed regularly after
each drug administration. Neurological function tests were
performed before the subject’s departure from the study
site. A complete physical examination including vital sign
measurements, a 12-lead ECG, and laboratory testing was
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also performed at the end of the study. Subjects were
regularly questioned on their health status during confine-
ment, and AEs were recorded, symptoms thoroughly
described, and followed up until satisfactory resolution.
Oral mucosal safety and local tolerability were assessed
by monitoring erythema, edema, or other AEs. A visual
inspection of the tongue, palate, and the oral mucosa was
performed prior to and 0.5 h after drug administration. This
inspection was also performed immediately after drug
administration as part of treatment compliance. Throughout
study confinement, the subjects were asked to self-report
any signs or symptoms of mouth irritation. Observation of
the tongue, palate, buccal mucosa, and surrounding area
was documented by using a four-point severity scale
(0 = no irritation, 1 = mild irritation, 2 = moderate irri-
tation and 3 = severe irritation). If tissue debris or
sloughing was present on the surface mucosa, a description
that included the degree (mild, moderate, or severe) was
noted.
Subjects were asked to complete a questionnaire on their
experience with the study products.
2.5 Statistical Methodology
The intra-subject variation following a single dose of
levetiracetam was estimated to be less than 20 %. Given
that the test-to-reference ratio of geometric LSmeans was
expected to fall within 92.5 and 107.5 %, it was estimated
that 33 subjects were needed to be included in the study to
meet the 80.00–125.00 % confidence interval (CI) range
with a statistical a priori power of at least 80 %.
Subjects who provided evaluable data for at least one of the
comparisons of interest (Treatment-1 vs. Treatment-2 or
Treatment-3 vs. Treatment-1) were included in the pharma-
cokinetic and statistical analysis. The natural logarithm (ln) of
Cmax, AUC0–T, and AUC0–?, and the rank transformation of
Tmax were used for statistical inference. Statistical analyses
were performed with an analysis of variance (ANOVA) model
and the two-sided 90 % CI of ratio of geometric LSmeans was
obtained between both products under fasting conditions
(Treatment-1 vs. Treatment-2). Food effect of levetiracetam
3DP fast melt was assessed using the ratio of geometric
LSmeans with corresponding 90 % CI calculated from the
exponential of the difference between fed and fasting condi-
tions (Treatment-3 vs. Treatment-1).
Statistical analyses were performed using SAS version 9
(SAS Institute, USA). SAS PROC MIXED was used for the
ANOVA model. The fixed factors included in the model
were the treatment received, the period at which it was
given, as well as the sequence in which each treatment was
received. A random factor was added for the subject effect
(nested within sequence). Statistical significance was
assessed at the two-sided 5 % level.
The safety population included participants who
received at least one treatment. Safety and tolerability
endpoints were summarized using descriptive statistics.
3 Results
3.1 Demographic
The 33 subjects included in this study (Table 1) were
healthy male and female individuals, most commonly
White (82 %), aged between 18 and 48 years (safety
population). All subjects in this study were non-smokers.
The results of the screening urinary drug and serology tests
(b-human chorionic gonadotropin qualitative) indicated
that all subjects were suitable for inclusion in the study. All
subjects received at least one dose of the study drug and
were included in the safety analysis and oral mucosa tol-
erability evaluation. Two subjects were withdrawn from
the study before dosing of period 2, one because of a
positive cannabinoids test result and one owing to an unmet
protocol requirement that could have had an impact on his
PK profile for this period (critical breakfast not completed
within 30 min before dosing). The latter returned to the
clinical site for period 3 of the study. Thus, 32 subjects
were included in the PK and statistical analysis (PK
population).
The study subjects included in the PK population were
fairly distributed between men and women, mean age of
31 years with a small percentage of subjects (4 %) aged
older than 41 years; and the mean body mass index was
24.5 kg/m2.
Table 1 Demographic and baseline characteristics of the subjects
included in the study
Characteristic Overall (safety population)
N = 33
Mean age (range), years 30 (18–48)











Mean BMI (range), kg/m2 24.35 (19–29)
BMI body mass index
232 S. Boudriau et al.
3.2 Pharmacokinetics
3.2.1 3DP Dosage Form and Water Intake
The 3DP fast-melt formulation of levetiracetam is designed
to disperse in the mouth within seconds in the presence of a
sip of water for ease of administration and swallowing. The
amount of water consumed by subjects during test product
administration was measured (range 2–30 mL, see
Table 2), and the elapsed time between the sip of water and
swallowing of the completely dispersed test product was
recorded for each subject. Of those administered the
levetiracetam 3DP fast-melt formulation, the mean amount
of water consumed was consistent between the fasting and
fed conditions. Similar elapsed disintegration time was
observed during fasting and fed conditions, with a mean
overall time of 11 s (Table 3).
3.3 Pharmacokinetics and Bioequivalence
Assessment
The mean PK values of levetiracetam after oral adminis-
tration as a 3DP fast melt or as a conventional immediate-
release tablet are summarized in Table 4.
Under fasting conditions, the ranked time to peak con-
centrations for the 3DP fast melt (test) and the reference
tablet were comparable (p = 0.5444), and both showed a
very fast absorption within approximately 30 min. Similar
values were also evident for the main PK parameters
evaluated in this study (Cmax, AUC0–t, and AUC0–inf), and
the terminal elimination half-life was approximately 7.1 h
for both formulations.
The 90 % CI for evaluating the bioequivalence and the
corresponding point estimates of the relative bioavailability
for the ln-transformed PK parameters are summarized in
Table 5. The geometric LSmeans for Cmax, AUC0–t, and
AUC0–inf were 106.45, 102.94, and 102.78 %, respectively.
The results presented herein show that the criteria used to
assess the relative bioavailability between these two for-
mulations under fasting conditions were all contained
entirely within the range of 0.80–1.25.
The mean plasma concentration-time profile of leve-
tiracetam 3DP tablet compared with that of the intact
conventional tablet is presented in Fig. 1.
3.4 Food Effect
The levetiracetam 3DP fast melt was administered after a
high-fat, high-calorie breakfast (136 kcal protein; 284 kcal
carbohydrate; 517.5 kcal fat), which was expected to
Table 2 Total volume of water consumed by subjects
Test fast Test fed
N 32 32
Mean (SD) (mL) 12 (5) 14 (7)
Median (mL) 12.5 13.0
SD standard deviation




Mean (SD) (s) 11 (11)b 11 (6)
Median (s) 7.5 10.0
SD standard deviation
a The drug was administered 30 min after the start of the breakfast
b One subject had an elapsed time of 62 s recorded with the initial
administration. Upon subsequent exposure, the elapsed time from sip
to swallowing the 3DP fast-melt formulation was reduced to 13 s for
this subject
Table 4 Comparison of the
pharmacokinetic parameters:
levetiracetam 3DP fast melt vs.
conventional levetiracetam
tablet









Meana (c.v.%) Meana (c.v.%) Meana (c.v.%)
Tmax (h) 0.58 (73.7) 0.58 (69.9) 4.00 (21.6)
Cmax (lg/mL) 33.273 (30.1) 30.480 (19.0) 20.481 (16.3)
AUC0–T (lgh/mL) 283.689 (20.0) 274.934 (18.2) 262.550 (15.1)
AUC0–? (lgh/mL) 292.927 (19.9) 284.300 (18.0) 272.565 (15.2)
Thalf (h) 7.13 (13.3) 7.14 (16.3) 7.19 (15.3)
Tmax time to maximum observed plasma concentration, Cmax maximum observed plasma concentration,
AUC0–T area under the plasma concentration–time curve from time zero to the time of the last measurable
concentration, AUC0–? area under the plasma concentration–time curve from time zero to infinity, Thalf
terminal elimination half-life, c.v. coefficient of variation, 3DP three-dimensional printing
a Median for Tmax
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provide the greatest effects on gastrointestinal physiology.
As indicated in Table 4, the administration of a high-fat,
high-calorie breakfast delayed the median Tmax by
approximately 3.5 h and resulted in a decrease of Cmax.
The Cmax geometric LS mean of levetiracetam in the fed
state was 63.9 % of the peak value of the fasting state but
the food intake had no effect on the extent of systemic
exposure as expressed by AUC (Table 6). The mean con-
centration–time curves of levetiracetam 3DP fast-melt
formulation under fasting and fed conditions are depicted
in Fig. 2.
3.5 Sex Subgroup Analyses
The administration of a 1000-mg levetiracetam dose was
further evaluated in male and female subgroups (Table 7).
Higher concentrations and AUCs were observed with both
formulations (3DP fast melt and conventional tablet) in
female subjects compared with male subjects. The median
Tmax showed a slight delay: 0.5 h (1 vs. 0.5 h) for the 3DP
fast melt (test) in female subjects, but was similar for the
conventional tablet (reference) in both subgroups. The
apparent elimination half-life was shorter for women when
compared with that of male subjects (*6.5 vs. 7.6 and
*6.3 vs. 7.8 h, respectively) for both formulations.
When sex was added as a fixed effect into the default
mixed-effect ANOVA model, significant differences
between female and male subjects were detected for all
observed ln-transformed PK parameters (p value Cmax
0.0002, AUC0–T 0.0004 and AUC0–? 0.0015) for the 3DP
fast melt vs. the conventional tablet under fasting condi-
tions (at 5 % significance level). Separate analysis was
done for ranked Tmax and significant difference was also
detected (p = 0.0439). Differences remain significant after
normalization of the ln-transformed PK parameters con-
sidering the individual weight and dose (p value Cmax
0.0019, AUC0–T 0.0002, and AUC0–? 0.0002).
Table 5 Ninety percent confidence intervals of ln-transformed
pharmacokinetic parameters of levetiracetam after a single 1000-mg
oral dose of the 3DP fast-melt (test formulation) and the conventional
tablet (reference formulation) under fasting conditions in healthy
volunteers
Parameter Ratio (test/reference) 90 % confidence intervals
Lower Upper
lnCmax 106.45 99.74 113.62
lnAUC0–T 102.94 100.93 105.00
lnAUC0–? 102.78 100.72 104.89
3DP three-dimensional printing, ln natural logarithm, AUC0–T area
under the plasma concentration–time curve from time zero to the time
of the last measurable concentration, AUC0–? area under the plasma

























Fig. 1 Mean levetiracetam
plasma concentration-time
(?standard deviation) curve
profiles (linear scale) after oral
administration of a single
1000-mg dose of test
formulation and a single
1000-mg dose of reference
tablet. 3DP three-dimensional
printing
Table 6 Ninety percent confidence intervals of ln-transformed
pharmacokinetic parameters between the administration of leve-
tiracetam 3DP fast melt under fed conditions vs. levetiracetam 3DP
fast melt under fasting conditions in healthy volunteers
Parameter Ratio (fed/fast) 90 % confidence intervals
Lower Upper
lnCmax 63.85 59.79 68.19
lnAUC0–T 94.45 92.58 96.36
lnAUC0–? 94.93 93.00 96.89
3DP three-dimensional printing, AUC0–T area under the plasma
concentration–time curve from time zero to the time of the last
measurable concentration, AUC0–? area under the plasma concen-
tration–time curve from time zero to infinity, Cmax maximum
observed plasma concentration, ln natural logarithm
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3.6 Water Intake
No significant trend or correlation was observed between
the amount of water ingested with the 3DP fast melt vs. the
measured levetiracetam plasma concentrations nor the
AUC (Cmax p value for the Pearson correlation coefficient
0.5100 and 0.7602, fasting and fed, respectively; AUC0–T
p value 0.6229 and 0.7058, fasting and fed, respectively)
(Fig. 3).
3.7 Safety
Single 1000-mg oral dose of the levetiracetam 3DP fast
melt (test product) was generally well tolerated when
administered under fasting and fed states. No medica-
tions were taken between the screening visit and the first
dosing. In addition, no AEs required the use of medi-
cations following the first dosing until the end of the
study. The incidence of drug-related AEs reported was
notably lower for levetiracetam (test) administered under
fed conditions (34 %) than for levetiracetam (test) and
the reference levetiracetam products administered under
fasting conditions (each 56 %). The majority of AEs
reported during the study were of mild (n = 79) or
moderate (n = 15) severity (Table 8). No severe AEs
were observed during the study. None of the AEs
reported after the administration of levetiracetam was
serious. No adverse events required the use of medica-
tions following the first dosing.
The most frequently reported drug-related AEs during
the study were of nervous system origin. The most com-
mon adverse events included somnolence, dizziness, and
fatigue.
No deaths or serious AEs were reported in the present





















Levetiracetam 3DP fast melt
- fasted
Levetiracetam 3DP fast melt
- fed
Fig. 2 Mean plasma
concentration-time (?standard
deviation) curve profiles (linear
scale) of levetiracetam 3DP fast
melt following the
administration of a high-fat,
high-calorie breakfast compared
with fasting conditions. 3DP
three-dimensional printing
Table 7 Comparison of the
pharmacokinetic parameters
between female and male
subjects for the levetiracetam
3DP fast melt and levetiracetam
conventional tablet under
fasting conditions















Meana (c.v.%) Meana (c.v.%) Meana (c.v.%) Meana (c.v.%)
Tmax (h) 1.00 (68.5) 0.67 (75.3) 0.50 (62.4) 0.50 (57.2)
Cmax (lg/mL) 38.190 (22.4) 34.475 (13.6) 29.448 (32.5) 27.372 (16.7)
AUC0–T (lgh/mL) 323.946 (17.0) 304.702 (17.0) 252.379 (13.6) 251.780 (13.9)
AUC0–? (lgh/mL) 331.870 (17.8) 312.097 (17.3) 262.639 (13.9) 262.679 (14.4)
Thalf (h) 6.47 (12.2) 6.34 (15.0) 7.641 (9.6) 7.77 (11.7)
Tmax time to maximum observed plasma concentration, Cmax maximum observed plasma concentration,
AUC0–T area under the plasma concentration–time curve from time zero to the time of the last measurable
concentration, AUC0–? area under the plasma concentration–time curve from time zero to infinity, Thalf
terminal elimination half-life, c.v. coefficient of variation, 3DP three-dimensional printing
a Median for Tmax
Bioavailability of a novel 3D Printed Levetiracetam 235
4 Discussion
Powder-liquid 3DP technology is being used to produce
high-dose solid oral products that can be offered in a
‘fast-melt’ or rapidly disintegrating formulation, to aid in
patient compliance and ensure ease of dosing and swal-
lowing. Fast melts manufactured by the 3DP process are
essentially wet-bound, uncompressed, highly porous for-
mulations with a shape similar to conventional tablets.
However, unlike conventional tablets, 3DP formulated
fast melts rapidly disintegrate within seconds in the
mouth, when exposed to a small volume of liquid. Taking
3DP formulated fast melts with a sip of liquid not only
facilitates rapid dispersion in the mouth but also aids in
the subsequent swallowing of the dispersed medication.
Unlike liquid solutions or suspensions, this mode of
administration does not require measurement or prepara-
tion outside the body, and ensures the entire dose may be
consumed without the question of residue on a measuring
device (e.g., cup or oral syringe).
4.1 Pharmacokinetics
Aprecia Pharmaceuticals Company developed a novel
1000-mg levetiracetam 3DP fast-melt formulation that was
designed to provide plasma concentration and systemic
exposure comparable to the reference product after
administration of a single dose in normal healthy volun-
teers. Moreover, the effect of food consumption on the PK
profile of this novel formulation was evaluated.
Fig. 3 Effect of water intake on
pharmacokinetic parameters.
a Under fasting conditions.
b Under fed conditions. Cmax
maximum observed plasma
concentration, AUC0–T area
under the plasma concentration–
time curve from time zero to the
time of the last measurable
concentration, extotal total
volume of water consumed by
subject
Table 8 Number of adverse events per treatment, classified by severity and causality
Treatments Adverse events (n)
Severity Causality
Mild Moderate Severe Reasonable possibility No reasonable possibility
Treatment-1 (test fast) 32 7 0 33 6
Treatment-2 (reference fast) 31 4 0 28 7
Treatment-3 (test fed) 16 4 0 13 7
Total no. of adverse events 79 15 0 74 20
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As noted above, the 3DP fast-melt formulation of
levetiracetam is designed to disperse rapidly in the mouth
when taken with a small amount of liquid. The actual
measurement of in situ disintegration times in the study
subjects showed that the tablets rapidly dispersed in the
mouth when taken with a sip of water (mean time from sip
to swallowing of 11 s), which is consistent with the in vitro
disintegration measurements (e.g., dispersion occurs on
average in 5–6 s for the 1000-mg formulation) [10]. The
amount of water used for dosing the product (test product
administered with a sip consisting of 2–30 mL; reference
product administered with 240 mL water) did not affect the
absorption of the drug and overall PK parameters were
comparable. Moreover, a variable amount of water taken
from the sip did not show any correlation with AUC or
Cmax for the 3DP fast-melt product.
As described before, the three-way crossover design was
found suitable to meet the objectives of the study. The
sample size was based on previous in-house data at
Algorithme Pharma to meet an expected test to reference
ratio of geometric LSmeans within 92.5 % and 107.5 %
and a power of at least 80 %. Sufficient subjects were
enrolled to account for the possibility of drop-outs, varia-
tions around the estimated intra-subject coefficient of
variation, and to conclude in favor of the hypothesis of
relative bioavailability with sufficient statistical power.
The results show that ratio of geometric LSmeans
and corresponding 90 % CI for the Cmax, AUC0–T, and
AUC0–? were all within the FDA BE acceptance range of
80.00–125.00 %, indicating that the 3DP levetiracetam fast
melt, as administered with a sip of liquid, is equivalent in
rate and extent of absorption to the conventional leve-
tiracetam tablet administered normally under fasting
conditions.
A subset analysis by sex indicated that the bioavail-
ability of levetiracetam was significantly higher in female
subjects compared with male subjects under fasting con-
ditions for both levetiracetam 3DP fast melt and conven-
tional tablet. Normalization by weight and dose could not
explain the differences. Coupez et al. also reported larger
Cmax and AUCs in female subjects and a delay in Tmax with
the administration of an oral levetiracetam solution [2].
Administration of a drug product with food may change
the bioavailability by affecting either the drug substance or
the drug product [11]. The effect of food on the leve-
tiracetam 3DP fast-melt formulation was evaluated using a
high-fat, high-calorie breakfast. The Cmax geometric LS
mean of levetiracetam in the fed state was 63.9 % of the
peak value of the fasting state. Additionally, the median
time to peak concentration was significantly delayed under
fed conditions by approximately 3.5 h. However, the food
intake had no effect on the extent of the systemic exposure.
Additionally, the mean apparent terminal elimination half-
life (Thalf) was similar in both conditions. Thus, food sig-
nificantly decreased peak values and delayed peak times of
the levetiracetam 1000-mg 3DP fast-melt formulation but
not the extent of absorption. These observations are con-
sistent with the PKs of the conventional levetiracetam
tablets in the fed state where a decrease Cmax of 20 % with
a delay of 4 h are reported [1]. Other studies also report a
delay in the absorption with a small decrease in the
exposure by 8–10 % [12], or in contrast describe the
absence of drug–food interactions [13]. None of the
reported effects were deemed of clinical significance.
4.2 Safety
The new 3DP fast-melt formulation of levetiracetam was
found to be safe and well tolerated when administered to
healthy volunteers. The most commonly experienced
adverse events included somnolence, dizziness, and fati-
gue. The safety profile observed in this study corresponds
to the one presented in the product’s monograph where the
most commonly reported AEs included somnolence,
asthenia, infection, and dizziness [1]. Furthermore,
behavioral/psychiatric symptoms such as hallucinations,
paranoid reaction, psychosis, and psychotic depression; as
well as coordination difficulties such as ataxia, abnormal
gait, and incoordination were shown to be reported after
the administration of levetiracetam. However, no abnormal
behavioral and neurological examinations were recorded
during this study. Serious hypersensitivity reactions with
dermatological involvement have been reported in associ-
ation with levetiracetam use [1]. In the present study, no
changes on the oral mucosa were noted for any subject
from the pre- to the post-dose evaluation. Minor hemato-
logical abnormalities were also reported in controlled
clinical trials in patients treated with levetiracetam for total
mean red blood cell count, mean hemoglobin, and mean
hematocrit [14]. One subject presented ecchymosis on the
thighs; however, her hematology tests were considered not
clinically significant. On-study vital signs and ECGs were
of no clinical significance.
Interestingly, the number of AEs related to the leve-
tiracetam 3DP fast melt was lower under fed conditions;
this could be related to the delayed and/or the lower peak
plasma values after the intake of food.
5 Conclusions
No clinically significant effects on vital signs, ECGs,
neurological examinations, or the oral mucosa were noted
and no serious AEs were reported during the study. A
single 1000-mg oral dose of the levetiracetam 3DP fast-
melt product was generally safe and well tolerated by the
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subjects included in this study. The safety profile of the
levetiracetam 3DP fast melt product was similar under both
fed and fasting conditions, and similar to the profile pre-
sented in the conventional or reference product’s mono-
graph. Overall, most subjects agreed that the mouth feel of
the 3DP fast-melt product was acceptable and easy to take
and swallow. In addition, the majority indicated the 3DP
fast-melt product disintegrated or melted quickly in their
mouth prior to swallowing, when taken with a small sip of
water.
The present study concludes that the levetiracetam
3DP fast melt is equivalent in rate and extent of
absorption to the conventional immediate-release tablet
when given in the fasted state. The rapid oral disinte-
gration for the 3DP fast melt did not affect the PK
profile of levetiracetam even though a delay and a lower
peak in the absorption were observed under fed condi-
tions. These effects are unlikely to be of clinical sig-
nificance with long-term administration, and may help to
reduce the AEs and facilitate compliance.
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